DAX24.856 -0,5%Est506.036 -0,2%MSCI World4.343 -0,1%Top 10 Crypto8,7200 -0,6%Nas23.066 -0,2%Bitcoin56.806 +0,7%Euro1,1878 ±0,0%Öl69,65 ±0,0%Gold5.054 -0,6%

GenfitAct. Aktie

Kaufen

Verkaufen

GenfitAct. Aktien-Sparplan GenfitAct. Aktien-Sparplan

6,66 EUR +0,16 EUR +2,38 %

11.02.2026

BMN

6,52 EUR +0,27 EUR +4,32 %

10.02.2026

PAR

GenfitAct. jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Bei einem anderen Broker handeln

Smartphone

Marktkap.324,93 Mio. EUR

KGV116,67Div. Rendite0,00%

WKNA0LGJ2

ISINFR0004163111

SymbolGNFTF

GenfitAct. Aktien News

Sortieren:Datum Meistgelesen

06.12.23GlobeNewswireGENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

16.11.23GlobeNewswireGENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

13.11.23GlobeNewswireGENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

09.11.23GlobeNewswireGENFIT Reports Third Quarter 2023 Financial Information

02.11.23GlobeNewswireGENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

26.09.23GlobeNewswireGENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

20.09.23GlobeNewswireGENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

05.09.23GlobeNewswireGENFIT to Participate in Upcoming Investor Conferences

10.08.23GlobeNewswireGENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

12.07.23GlobeNewswireGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

30.06.23GlobeNewswireIpsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

07.06.23GlobeNewswireGENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

31.05.23GlobeNewswireGENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

24.05.23GlobeNewswireGENFIT: May 24, 2023 Combined Shareholders Meeting results

23.05.23GlobeNewswireGENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

11.05.23GlobeNewswireGENFIT Reports First Quarter 2023 Financial Information

09.05.23GlobeNewswireGENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

27.04.23GlobeNewswireGENFIT Announces Publication of Extra-Financial Performance Report 2022

19.04.23GlobeNewswireGENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

18.04.23GlobeNewswireGENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F

13.04.23GlobeNewswireGENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update

28.02.23GlobeNewswireGENFIT Announces Revenues and Cash Position as of December 31, 2022

GenfitAct. News

GenfitAct. News: auf dieser Seite finden Sie alle GenfitAct. News und Nachrichten zur GenfitAct. Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch GenfitAct. News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um GenfitAct. News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.